|
Solvent |
mg/mL |
mM |
| Solubility |
| Soluble in DMSO |
0.0 |
100.00 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
364.54
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Kobayashi T, Kiyokawa Y, Takeuchi Y, Mori Y. Pretreatment with CP-154526 blocks the modifying effects of alarm pheromone on components of sexual behavior in male, but not in female, rats. Chem Senses. 2011 Sep;36(7):623-32. doi: 10.1093/chemse/bjr017. Epub 2011 Apr 18. PMID: 21502338.
2: Nalivaiko E, Blessing WW. CRF1-receptor antagonist CP-154526 reduces alerting-related cutaneous vasoconstriction in conscious rabbits. Neuroscience. 2003;117(1):129-38. doi: 10.1016/s0306-4522(02)00818-7. PMID: 12605899.
3: Lawrence KM, Jones RC, Jackson TR, Baylie RL, Abbott B, Bruhn-Olszewska B, Board TN, Locke IC, Richardson SM, Townsend PA. Chondroprotection by urocortin involves blockade of the mechanosensitive ion channel Piezo1. Sci Rep. 2017 Jul 11;7(1):5147. doi: 10.1038/s41598-017-04367-4. PMID: 28698554; PMCID: PMC5505992.
4: Su J, Tanaka Y, Muratsubaki T, Kano M, Kanazawa M, Fukudo S. Injection of corticotropin-releasing hormone into the amygdala aggravates visceral nociception and induces noradrenaline release in rats. Neurogastroenterol Motil. 2015 Jan;27(1):30-9. doi: 10.1111/nmo.12462. Epub 2014 Oct 31. PMID: 25359531.
5: Zaretsky DV, Zaretskaia MV, Sarkar S, Rusyniak DE, DiMicco JA. The non- peptide CRH1-antagonist CP-154,526 elicits a paradoxical route-dependent activation of the HPA axis. Neurosci Lett. 2017 Jul 13;653:1-6. doi: 10.1016/j.neulet.2017.05.012. Epub 2017 May 13. PMID: 28511913.
6: Navarro-Zaragoza J, Núñez C, Laorden ML, Milanés MV. Effects of corticotropin-releasing factor receptor-1 antagonists on the brain stress system responses to morphine withdrawal. Mol Pharmacol. 2010 May;77(5):864-73. doi: 10.1124/mol.109.062463. Epub 2010 Feb 16. PMID: 20159948.
7: Sotomayor-Zárate R, Abarca J, Araya KA, Renard GM, Andrés ME, Gysling K. Exposure to repeated immobilization stress inhibits cocaine-induced increase in dopamine extracellular levels in the rat ventral tegmental area. Pharmacol Res. 2015 Nov;101:116-23. doi: 10.1016/j.phrs.2015.08.015. Epub 2015 Aug 28. PMID: 26318765.
8: Nijsen M, Ongenae N, Meulemans A, Coulie B. Divergent role for CRF1 and CRF2 receptors in the modulation of visceral pain. Neurogastroenterol Motil. 2005 Jun;17(3):423-32. doi: 10.1111/j.1365-2982.2005.00644.x. PMID: 15916630.
9: Seymour PA, Schmidt AW, Schulz DW. The pharmacology of CP-154,526, a non- peptide antagonist of the CRH1 receptor: a review. CNS Drug Rev. 2003 Spring;9(1):57-96. doi: 10.1111/j.1527-3458.2003.tb00244.x. PMID: 12595912; PMCID: PMC6741649.
10: Schwetz I, Bradesi S, McRoberts JA, Sablad M, Miller JC, Zhou H, Ohning G, Mayer EA. Delayed stress-induced colonic hypersensitivity in male Wistar rats: role of neurokinin-1 and corticotropin-releasing factor-1 receptors. Am J Physiol Gastrointest Liver Physiol. 2004 Apr;286(4):G683-91. doi: 10.1152/ajpgi.00358.2003. Epub 2003 Nov 13. PMID: 14615283.
